Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review

This JAMA Cardiology review is the ApoB argument at full maturity — the same case Sniderman has pressed for over a decade, now co-authored with a roster of lipid heavyweights and backed by causal genetic evidence.

The synthesis is comprehensive: atherosclerosis is driven by the number of ApoB-containing particles trapped in the artery wall, not the cholesterol they carry; ApoB and LDL-C are discordant in 20–60% of people, especially those with high triglycerides, obesity, or diabetes; and in those cases risk follows ApoB. Crucially, Mendelian randomization confirms that lowering ApoB lowers risk in proportion, regardless of the drug — moving the claim from association to causation. Because each atherogenic particle carries exactly one ApoB, measuring it directly counts the causal agents.

The practical takeaway is now-familiar but here at its most authoritative: measure ApoB to refine risk and guide therapy intensity, particularly in metabolic disease where LDL-C deceives. The resistance is clinical inertia, the LDL-centric legacy, and payer reluctance over a test that is, in fact, cheap and standardized.

We rate the evidence moderate as a document (a narrative review, with several co-authors disclosing industry ties), but bolstered by the causal, genetic evidence it synthesizes. Its clinical significance is very high — this is among the papers that moved ApoB from a specialist’s cause into mainstream guidelines, addressing risk in the vast metabolically unhealthy population.